About THERAVIA
THERAVIA is a specialty bio-pharmaceutical company dedicated to the discovery, preclinical development and commercialization of innovative therapies that cure human infectious diseases.
THERAVIA clinical R&D is based on patentable small molecules, nucleoside analogues reflecting current research and product development in the area of targeted drug delivery. Currently three lead product candidates are in advanced preclinical development, against Flaviruses (Dengue Virus, Hepatitis C Virus) and HIV.
THERAVIA collaborates with University of Montpellier, the CNRS & the Institute pour la Recherche et le Development.
Founded in 2002, THERAVIA is privately held, with corporate offices in Montpellier, France and Birmingham, AL, USA. Out-licensing opportunities are available.
USA Contact:
Omar Safarjalani, MD.
Chief Scientific Officer, Clinical Research and Medical Affairs President, USA.
2700 3rd Av. South
Birmingham, AL 35233
USA.
(205)956-6330
THERAVIA@gmail.com |